Metagenomi Therapeutics, Inc. (MGX) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.73; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.61; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.55; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.54; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $1.13
- Previous close
- $1.14
- Change
- -$0.01
- Change (%)
- -0.88%
- Close date
- 2026-09-29
- Previous close date
- 2026-09-28
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- MGX
- -30.25%
- S&P 500
- (m)
1 year
- MGX
- -50.87%
- S&P 500
- (m)
3 years
- MGX
- (m)
- S&P 500
- (m)
5 years
- MGX
- (m)
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -0.73
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -0.73 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -0.61 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | -0.55 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | -0.54 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | -0.68 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual -2.36
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | -2.36 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -2.36 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | -20.05 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
31 Mar 2026 ■ Revenue 1.25M ■ Earnings -23.06M — Profit margin -1847.68%
31 Dec 2025 ■ Revenue 25.21M ■ Earnings -87.87M — Profit margin -348.54%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $1.13 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning MGX
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 31 Mar 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-85.89M
- Operating margin · 12 months
- -415.48%
- Profit margin
- -384.61%
- Return on assets · 12 month
- -34.71%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 119.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 156.74K
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -0.88%*
- Total return · month
- -5.04%*
- Total return · quarter
- -5.83%*
- Total return · half year
- -14.39%*
- Total return · year to date
- -30.25%*
- Total return · 1 year
- -50.87%*
- Total return · 3 years
- (m)
- Total return · 5 years
- (m)
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 396.72%
- Revenue · 12 month
- $22.33M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-87.22M
- Free cash flow · 12 months (USD)
- $-87.54M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
Metagenomi Therapeutics, Inc. Overview
View more →(m)
(m)
- SEC CIK
- 1785279
- Industry (SIC)
- 2836 Biological Products, (No Diagnostic Substances)
- Country of operation
- United States
- Business address
- 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, California, 94608, United States
- Fiscal year end
- 1231
- Phone
- (510) 871-4880
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |